













doi:10.101Decreased Serum Testosterone Levels in Long-Term
Adult Survivors with Fatty Liver after Childhood Stem
Cell Transplantation
Hiromi Hyodo,1 Hiroyuki Ishiguro,1 Yuichiro Tomita,1 Hiromitsu Takakura,1 Takashi Koike,1
Takashi Shimizu,1 Tsuyoshi Morimoto,1 Hiromasa Yabe,2 Miharu Yabe,3 Sei-ichiro Kojima,4
Koichi Shiraishi,4 Takashi Minemura,5 Shunichi Kato2Fatty liver and male gonadal dysfunction are potential late effects of therapy in adult survivors treated with
stem cell transplantation (SCT) in childhood. Obesity and metabolic syndrome also are associated with low
serum testosterone levels in the general population. However, the relationship between the degree of fatty
liver and changes in serum testosterone levels in adult survivors has not been fully studied. We reviewed the
clinical records of 34 male patients who received allogeneic SCT in childhood or adolescence. The median
age at SCTwas 10.0 years, and the median follow-up after SCTwas 15.9 years. All but one patient showed no
tendency toward overweight/obesity during the follow-up period. Fatty liver was diagnosed by ultrasound in
15 patients at 4 to 20 years after SCT. Patients who received cranial radiation therapy before SCTwere more
likely to develop fatty liver and insulin resistance. Moreover, fatty liver was statistically associated with
decreased serum testosterone levels, whereas nonfatty liver was not (median, 527 ng/dL [range, 168-944
ng/dL] versus 302 ng/dL [165-698 ng/dL]; P\.0001). Changes in testosterone levels after SCTare affected
not only by primary gonadal dysfunction but also by subsequent development or exacerbation of fatty liver.
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ObesityINTRODUCTION
Continuing advances in the management of child-
hood malignancies are producing a rapidly enlarging
group of childhood cancer survivors [1-3]. With
survival rates currently at 70% to 80%, an estimated
one in 700 of the young adult population in Japan is
a long-term survivor of childhood cancer [4,5].
Children and adult survivors commonly experience
morbidity, generally related to the treatment they
received to cure their cancer rather than to the cancer
itself. Treatment-related morbidity is extraordinarily1Department of Pediatrics; 2Department of Cell Trans-
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6/j.bbmt.2012.01.004diverse. Childhood cancer survivors are at significant
risk for developing late effects after successful cancer
treatment during childhood. In particular, endocrine
system disorders are common, affecting up to 40% of
childhood cancer survivors and include gonadal dys-
function, metabolic disorders, thyroid dysfunction,
and growth impairment [6-11].
Fatty liver is associated with metabolic abnormali-
ties characterized by obesity [12], type 2 diabetes mel-
litus (DM) [13], dyslipidemia [14], and hypertension
[15], each of which also carries a cardiovascular disease
risk. Moreover, fatty liver is increasingly recognized as
a major cause of liver-related morbidity and mortality
in the general population because of its potential to
progress to cirrhosis and liver failure [16]. Numerous
epidemiologic investigations in the general population
have established associations between low serum
testosterone level and obesity and metabolic syndrome
[17-19]; however, the mechanism underlying these
conditions is incompletely understood. In particular,
whether low serum testosterone causes metabolic
syndrome or vice versa has not been clarified. We
hypothesized that fatty liver with insulin resistance
may be considered as the cause of reduced
testosterone levels in adult childhood cancer survivors.1119
1120 Biol Blood Marrow Transplant 18:1119-1127, 2012H. Hyodo et al.Although metabolic syndrome and gonadal
dysfunction in adult survivors have been well docu-
mented, a longitudinal study investigating the rela-
tionship between the degree of fatty liver and
changes in gonadal function in survivors of childhood
stem cell transplantation (SCT) has not yet been
reported, and the mechanism of these conditions has
not been completely elucidated. To test our hypothe-
sis, we performed a longitudinal retrospective study of
adult male survivors of childhood cancer treated with
SCT to investigate the relationship between fatty liver
and gonadal function.METHODS
Patients
We reviewed the clinical records of 98 male pa-
tients who underwent SCT at Tokai University
Hospital between 1982 and 1997 and had annual
follow-up. Inclusion criteria were survival for at least
5 years after SCT, age at least 18 years at the last eval-
uation, and no past history of or laboratory findings
suggesting liver dysfunction or endocrine or metabolic
abnormalities before SCT. Thirty-four adult survivors
met these criteria and were included in this analysis. In
these 34 patients, the median age at the time of SCT
was 10.0 years, the median age at the last evaluation
was 25.1 years, and the median duration of follow-up
after SCT was 16.3 years (Table 1). To examine the
risk factors for developing fatty liver, the study popu-
lation was categorized into four groups according to
age at SCT, primary disease, presence of fatty liver,
doses of radiation to the brain and testes, and condi-
tioning regimen received: the cranial radiation therapy
(CRT) plus total body irradiation (TBI) group, the
TBI group, the thoracoabdominal irradiation (TAI)
group, and the chemotherapy (Chemo) group. Patient
characteristics are summarized in Table 1. Written in-
formed consent was obtained from all patients and/or
their parents. This study was approved by Tokai Uni-
versity’s Clinical Research Review Committee.Transplantation Procedure
In addition to conventional chemotherapy, three
patients with acute lymphoblastic leukemia (ALL)
and one patient with non-Hodgkin lymphoma
(NHL) received prophylactic CRT (one with 12 Gy
and three with 18 Gy) at 1 to 5 years before SCT. In
28 patients, conditioning regimens consisted of irradi-
ation with or without cyclophosphamide (CY) and/or
other drugs; 8 to 12 Gy of TBI was given in four to
six fractions for patients with malignant diseases,
and 6 to 8 Gy of TAI was given in three or four frac-
tions for patients with nonmalignant diseases. The
testes were shielded from radiation during the TAIprocedures. The remaining six patients received con-
ditioning without irradiation. Prophylaxis against
graft-versus-host disease (GVHD) varied during the
time period, with methotrexate, cyclosporine, or
a combination of the two drugs used.
AnthropometricMeasures of BodyComposition
All patients had achieved their final height at the
last evaluation. Body mass index (BMI) was calculated
as weight in kilograms divided by the height in meters
squared (kg/m2). Patients with a BMI$25 kg/m2 were
classified as overweight/obese, and those with a
BMI #18.5 kg/m2 were classified as underweight in
accordance with World Health Organization criteria
[20]. Waist circumference (WC) was measured at the
level of the superior iliac crest. Abdominal adiposity
was defined as a WC-to-height ratio .0.5 [21-23].
Bioelectronic impedance analysis was performed to
measure body fat by (InnerScan; Tanita, Tokyo,
Japan).
Evaluation of Fatty Liver
Fatty liver was evaluated by a total of 303 longi-
tudinal ultrasound examinations performed in the 34
patients during the follow-up period. Up to 1994,
Hitachi EUB340 (Hitachi, Tokyo, Japan) and Yoko-
gawa RT2800 and RT3000 (GE Yokogawa Medical
Systems, Tokyo, Japan) ultrasound systems were used
to evaluate fatty liver. After 1995, this evaluation was
done using an Aloka SSD 650CL system (Aloka,
Tokyo, Japan). Of the four criteria used for the diagno-
sis of fatty liver—hepatorenal echo contrast (HRE),
liver brightness (LB), deep attenuation (DA), and vascu-
lar blurring (VB)—the first two were used as definitive
criteria, and the last two were taken into account as
needed [24]. The degree of fatty liver was classified as
follows: severe, both HRE and LB positive; moderate,
eitherHREorLB positive and/or eitherDAorVBpos-
itive; or mild, HRE, LB, DA, and VB negative. In all
cases, two gastroenterology specialists separately con-
firmed the diagnosis without access to detailed informa-
tion about the patient’s background. Abdominal
computed tomography was performed in 23 patients,
and the results were coordinated with fatty liver diag-
nosedbyultrasound, asdescribed indetail elsewhere [9].
Evaluation of Glucose and Lipid
Metabolism Profiles
An overnight fasting blood sample was obtained
from all patients for the measurement of plasma glu-
cose, plasma insulin, serum triglycerides (TG), serum
total cholesterol (TC), serum high-density lipoprotein
cholesterol (HDL-C), serum low-density lipoprotein-
cholesterol (LDL-C), and serum-free fatty acid. To
convert our data to SI units, multiply plasma glucose
by 0.0555 (result in mmol/L), plasma insulin by
Table 1. Patient Characteristics
All (n 5 34) Fatty Liver (n 5 15) Non-Fatty Liver (n 5 19) P Valuea
Age at SCT, years, median (range) 10.0 (0.7-15.8) 8.8 (0.7-15.5) 10.5 (0.9-15.8) .627
Age at last evaluation, years, median (range) 25.1 (18.0-36.0) 24.8 (18.0-36.0) 25.3 (18.0-33.2) .945
Dollow-up duration after SCT, years, median
(range)
16.3 (6.7-27.7) 16.0 (6.7-27.7) 16.8 (7.6-24.8) 1
Primary disease, n
Malignant disease
Acute lymphoblastic leukemia 8 5 3
Acute myelogenous leukemia 6 3 3
Chronic myelogenous leukemia 3 2 1
Non-Hodgkin lymphoma 4 1 3
Nonmalignant disease
Aplastic anemia 8 2 6
Other 5 2 3
Cranial radiation before SCT, n 4 3 1
Conditioning regimen for SCT, n
TBI + cyclophosphamide + other drugs 20 9 11
Thoracoabdominal irradiation +
cyclophosphamide + other drugs
8 3 5
Chemotherapy 6 3 3
Radiation therapy, n
Brain 0 Gy 14 6 8
Brain $8 Gy 20 9 11
Testes 0 Gy 14 6 8
Testes 8-12 Gy 20 9 11
aFor comparison of fatty liver and non-fatty liver.
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serum TC, serum HDL-C, and serum LDL-C by
0.0259 (mmol/L).
Insulin resistance was estimated by the homeo-
static model assessment of insulin resistance
(HOMA-IR) using the formula fasting plasma insulin
(mU/L)  plasma glucose (mg/dL)/405, with a value
$2.5 indicating insulin resistance. The oral glucose
tolerance test (OGTT) was performed in 25 patients
for evaluation of glucose and insulin metabolism.
For the OGTT, the patient was given glucose at
1.75 g/kg (maximum, 75 g) after a 12-h overnight
fast, and samples for measurement of plasma glucose
and plasma insulin were drawn at baseline and every
30 minutes for up to 120 minutes. Hyperinsulinemia
was defined as a fasting plasma insulin value of $13
mU/L or a peak plasma insulin level $150 mU/L on
the OGTT. Definitions of DM and impaired glucose
tolerance were based on Japan Diabetes Society crite-
ria. The presence of either type 1 or type 2 DM was
diagnosed by a fasting plasma glucose level $126
mg/dL and/or a plasma glucose level $200 mg/dL at
2 h after the glucose load. A random plasma glucose
value .200 mg/dL was also considered to indicate
DM. A fasting plasma glucose level\110 mg/dL and
a 2-h plasma glucose level\140 mg/dL were consid-
ered normal values. Impaired glucose tolerance was di-
agnosed in patients with values that were not normal
but that did not indicate DM.
Evaluation of Metabolic Syndrome
Metabolic syndrome was defined according to
the criteria published by a committee convened toestablish the definition and diagnostic criteria of
metabolic syndrome in Japan [25]: central obesity
(WC $85 cm in males) and the presence of at least
two of the following factors—serum TG $150 mg/
dL and/or HDL-C\40 mg/dL, systolic blood pres-
sure $130 mm Hg and/or diastolic blood pressure
$85mmHg, and fasting plasma glucose$110mg/dL.
Evaluation of Endocrine Function
Onset of puberty was defined as a testicular volume
$4 mL [26]. Testicular volume was measured with an
orchidometer, as described by Prader [27]. Testicular
Leydig cell function and germinal epithelium damage
were evaluated by measurement of basal serum
luteinizing hormone (LH) level, basal serum follicle-
stimulating hormone (FSH) level, and serum testos-
terone level before SCT and annually during the
follow-up period. The normal basal serum LH and
FSH levels at our institutions were\9 mIU/mL and
\14 mIU/mL, respectively, and the normal range of
serum testosterone of the patients in their 20s and
30s was 131-871 ng/dL. Partial Leydig cell dysfunc-
tion and partial germinal epithelium damage were de-
fined by either increased basal LH level ($15 IU/mL)
or increased basal FSH level ($20 IU/mL) with a nor-
mal testosterone level. To convert to SI units, serum
testosterone values were multiplied by 0.0347 (results
in nmol/L). Plasma sex hormone-binding globulin
(SHBG) levels and free testosterone measurements
were performed by Special Reference Laboratories
(Tachikawa, Japan). All analyses except plasma
SHBG and free testosterone were performed in our
hospital’s routine clinical laboratory. Blood draws for
1122 Biol Blood Marrow Transplant 18:1119-1127, 2012H. Hyodo et al.endocrine tests were performed with the patient in
a morning fasting state, to avoid diurnal hormonal
variation.
Statistical Analysis
Because the data had a skewed distribution, values
are presented as median and range. Differences in
anthropometric and laboratory variables among
groups were analyzed using the Kruskal-Wallis test
with Dunn’s multiple comparison test. The Mann-
Whitney test was used to compare differences between
groups. Kaplan-Meier survival curves were con-
structed to assess the probability of fatty liver, and
the log-rank test was used to compare survival curves.
All statistical analyses were performed with the statis-
tical package GraphPad Prism 5 for Mac OS X
(GraphPad Software, La Jolla, CA). A P value\.05
was considered statistically significant.RESULTS
Anthropometrics
Among the 34 patients, only one (unique patient
number [UPN] 105), who had received chemotherapy
only, had a BMI .25 kg/m2 (26.2 kg/m2) at the last
evaluation. However, 11 patients had a BMI \18.5
kg/m2 (one patient in the CRT1TBI group, seven
patients in the TBI group, two patients in the TAI
group, and one patient in the Chemo group). No
patient satisfied the criteria for metabolic syndrome,
although three patients had a WC .85 cm (one with
a WC of 86.7 cm in the CRT1TBI group, one with
a WC of 90.0 cm in the TAI group, and one with
a WC of 92.2 cm in the Chemo group).
Fatty Liver
All 34 patients exhibited liver function within the
normal range during the follow-up period, although
one patient who received TBI (UPN 118) showed
a transient increase in transaminase levels after SCT,
and two patients had a positive hepatitis C virus-
RNA test result (UPNs 64 and 100 in the TAI group).
Information on daily alcohol consumption was
obtained from all patients by self-report. The majority
of the patients were nondrinkers or drank only
minimally. Fatty liver was diagnosed in 15 patients
(44%) by ultrasound during the follow-up period
(Figure 1). The patients with fatty liver showed no ten-
dency toward overweight/obesity during the follow-up
period, however; the mean BMI in these patients was
18.8 kg/m2 (range, 15.9-23.0 kg/m2) at the last evalu-
ation (Table 1). No relationships between the develop-
ment of fatty liver and age at SCT, primary disease, or
GVHD were observed. Concerning the mode of irra-
diation, the prevalence of fatty liver was higher in the
CRT1TBI group compared with the TBI, TAI, andChemo groups (75%, 38%, 38%, and 50%, respec-
tively), although the difference among groups was
not significant because of the small number of patients
in each group (P 5 .070; log-rank test) (Figure 1). In
five patients (UPN 91 in the CRT1TBI group,
UPNs 1 and 11 in the TBI group, UPN 215 in the
TAI group, and UPN 255 in the Chemo group), fatty
liver improved with exercise and dietary regimens pro-
vided by physicians and dieticians during the follow-up
period (Figure 1).
Evaluation of Lipid and Glucose Metabolism
Studies of lipid and glucose metabolism were per-
formed to investigate the mechanism of development
of fatty liver in patients who underwent SCT. Median
TG and HDL-C levels were statistically significantly
different between patients with fatty liver and those
without fatty liver (Table 2). Moreover, the presence
of fatty liver was significantly associated with increased
insulin resistance as determined by HOMA-IR score
(P 5 .032).
Evaluation of Endocrine Function
Puberty started spontaneously in all patients ac-
cording to increases in testicular volume ($4 mL),
and all patients had developed adult genitalia (Tanner
stage V) at the last evaluation. Serum testosterone level
reached the adult range at some point between adoles-
cence and adulthood after SCT in all patients (data not
shown). To clarify the relationship between testicular
irradiation and serum testosterone levels, patients
were divided into two groups, the testicular irradiation
group and the no testicular irradiation group. The
median serum testosterone level was not significantly
different between the two groups (448 ng/dL in the
testicular irradiation group versus 468 ng/dL in the
no testicular irradiation group), but serum LH and
FSH levels were significantly higher in the testicular
irradiation group (9.6 mIU/mL and 33.0 mIU/mL
versus 5.9 mIU/mL and 14.3 mIU/mL; P \ .0001)
(Figure 2A-C). These findings indicate that testicular
irradiation did not affect testosterone production.
On the other hand, the presence of fatty liver was sta-
tistically associated with decreased serum testosterone
levels (median, 527 ng/dL [range, 168-944 ng/dL] in
patients with fatty liver versus 302 ng/dL [165-698
ng/dL] in those without fatty liver; P\ .0001). More-
over, severe fatty liver tended to be associated with
lower median serum testosterone levels compared
with moderate, mild, and nonfatty liver (273 ng/dL,
333 ng/dL, 345 ng/dL, and 530 ng/dL, respectively;
P\ .0001) (Figure 2D-F). Decreased serum testoster-
one levels were associated with the development and
progression of fatty liver, and recovery of serum testos-
terone levels was observed after resolution of fatty liver
by exercise and diet in three patients (UPNs 011, 044,
Figure 1. Changes in fatty liver in adult survivors of childhood SCT. The degree of fatty liver is classified as follows:,, absence; , mild; , moderate;
-, severe; 1, existence; 1/ -, improved; +, SCT.
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tively correlated with HOMA-IR score (Spearman’s
rank correlation: r 5 -0.216; P 5 .375), but were
positively correlated with serum testosterone levels
(r 5 0.498; P 5 .030).DISCUSSION
This is the first study of adult survivors of
childhood cancer treated with SCT to indicate a
relationship between the degree of fatty liver and
changes in serum testosterone levels after SCT. Our
novel finding is that severe fatty liver presenting with
insulin resistance is associated with decreased serum
testosterone levels during the follow-up period after
SCT. The incidence of fatty liver with decreased
serum testosterone level was not associated with either
overweight/obesity or metabolic syndrome in these
patients who received SCT. These findings highlightthe increased health risks in adult survivors of
childhood SCT.
Fatty liver is increasingly recognized as a major
cause of liver-related morbidity and mortality because
of its potential to progress to cirrhosis and liver failure.
In a previous study, we found an 18% to 27% preva-
lence of fatty liver in Japanese male subjects in their
20s and 30s [24]. However, in the current study, the
prevalence of fatty liver was 44% in male adult survi-
vors who were not overweight/obese during the
follow-up period. These results indicate that SCT
may affect the prevalence of fatty liver in adult survi-
vors, and that these survivors aremore likely to develop
fatty liver compared with the general Japanese popula-
tion.Moreover, the prevalence of fatty liver was greater
in patients who received 24 to 30 Gy to the brain com-
pared with those who received 8 to 12Gy or 0Gy. This
suggests that radiation therapy to the brain may be
a contributing factor to the development of fatty liver
in adults who underwent SCT during childhood.
Table 2. Anthropometric Measurements, Liver Dysfunction Data, and Lipid and Glucose Metabolism Data in Adult Survivors of
Childhood SCT
All (n 5 34) Fatty Liver (n 5 15) Non-Fatty Liver (n 5 19) P Valuea
Anthropometric measures
Height, cm 159.1 (139.2-172.4) 158.5 (139.2-172.4) 159.7 (145.1-172.0) .716
Weight, kg 47.5 (31.3-72.8) 46.1 (37.6-67.1) 49.2 (31.3-72.8) .500
Waist circumference, cm 70.3 (53.0-92.2) 68.8 (61.5-82.0) 71.9 (53.0-92.2) .728
BMI, kg/m2 19.3 (13.8-26.2) 18.8 (15.9-23.0) 20.2 (13.8-26.2) .659
WC-to-height ratio 0.4 (0.4-0.6) 0.5 (0.4-0.5) 0.4 (0.4-0.6) .977
Body fat, %
Liver dysfunction
Aspartate aminotransferase, U/L 27 (15-74) 36 (20-74) 27 (15-68) .183
Alanine aminotransferase, U/L 27 (13-183) 32 (15-183) 23 (13-99) .167
Gamma-glutamyl transpeptidase, U/L 34 (14-224) 92 (14-224) 29 (19-175) .042
Lipid and glucose metabolism
TG, mg/dL 107 (35-409) 113 (67-409) 91 (35-185) .038
TC, mg/dL 203 (148-294) 195 (157-294) 207 (148-250) .851
HDL-C, mg/dL 63 (36-114) 47 (36-114) 67 (53-98) .046
LDL-C, mg/dL 128 (71-892) 135 (86-892) 127 (71-676) .805
Free fatty acid, mEq/L 0.60 (0.2-1.3) 0.60 (0.2-1.3) 0.50 (0.2-1.3) .351
HOMA-IR 1.9 (0.5-9.4) 3.5 (0.9-9.4) 1.6 (0.5-6.3) .032
Data are presented as median (range). To convert to SI units, multiply serum TG by 0.0113 (mmol/L) and multiply serum TC, serum HDL-C, and serum
LDL-C by 0.0259 (mmol/L).
aFor comparison of fatty liver and non-fatty liver.
1124 Biol Blood Marrow Transplant 18:1119-1127, 2012H. Hyodo et al.The present study included an insufficient number of
patients on which to base any definitive conclusions,
however, and additional prospective and multicenter
studies in larger populations are needed to investigate
the mechanism of this effect.
Many previous studies have reported low plasma
testosterone levels in men with metabolic syndrome
or type 2 DM [28,29]. Visceral obesity suppresses
testosterone production, and low plasma testosteroneFigure 2. Comparisons of serum testosterone levels (A andD), basal serum L
the middle 50th percentile of the value. The lower and upper boundaries of the
top of the bar showmaximum and minimum values, respectively. The degree of
severe. Significant differences are shown between *testicular irradiation versus
(P\.001), #moderate fatty liver versus nonfatty liver (P\.001), and ##severlevels induce visceral obesity and insulin resistance.
Kapoor et al [30] and others [31,32] reported
randomized double-blind, placebo-controlled studies
of the effect of testosterone replacement therapy on
correction of metabolic syndromemarkers and inflam-
mation in hypogonadal men. They found significant
improvements in weight, BMI, WC, and insulin level
in the testosterone treatment group compared with
the placebo group, and concluded that the decreaseH levels (B and E), and basal serum FSH levels (C and F). The box contains
box indicate the 25th and 75th percentiles, respectively. The bottom and
fatty liver was classified as follows: 0, absence; 1, mild; 2, moderate; or 3,
no testicular irradiation (P\.0001), **mild fatty liver versus nonfatty liver
e fatty liver versus nonfatty liver (P\.001).
Figure 3. Typical relationship between changes in serum testosterone levels and degree of fatty liver in adult survivors of childhood stem cell trans-
plantation: (A) UPN 011, (B) UPN 044, (C) UPN 212.
Biol Blood Marrow Transplant 18:1119-1127, 2012 1125Decreased Testosterone Level and Fatty Liver after SCTin testosterone levels with aging was one of the causes
of metabolic syndrome.
Little is known about whether the metabolic syn-
drome itself may predict the development of hypogo-
nadism, however. One study reported that men with
metabolic syndrome had a 2.6-fold increased risk of
developing hypogonadism after 11 years [33]. Thus,
prevention of abdominal obesity and accompanying
metabolic syndrome may reduce the risk of hypogo-
nadism in men. In other studies, weight loss and
weight maintenance in men with mainly generalized
obesity or abdominal obesity and metabolic syndrome
brought about sustained increases in free testosterone
levels [34,35]. The prevalence of hypogonadism, as
defined by total testosterone levels, decreased from
48% at baseline to 21% after weight loss and 12
months of successful weight maintenance. Weight
loss and weight maintenance increased testosterone
levels in men with metabolic syndrome after
improvement of fatty liver.
This finding of an inverse association between
metabolic abnormalities, including insulin resistance,
and serum testosterone level is in good agreement
with the results of the present study. Fatty liver was
more prevalent in patients who received radiation to
the brain before undergoing SCT than in those who
did not. Although testicular irradiation contributed
to damage to the testicular germinal epithelium, tes-
tosterone production was maintained during the
follow-up period even in patients who received radia-
tion to the testes. Moreover, the degree of fatty liver
in patients with insulin resistance was associated with
the degree of decreased testosterone secretion. Appro-
priate exercise and dietary regimens during the follow-
up period improved not only insulin resistance, but
also fatty liver, and recovery of testosterone secretion
followed. Based on these findings, the development
and progression of fatty liver in adult survivors of
childhood cancer treated with SCT can be considered
the cause of, rather than the result of, reduced testos-
terone levels.
A previous cross-sectional clinical study found an
inverse correlation between serum testosterone leveland fasting insulin level [36]. Men with insulin resis-
tance, such as those with obesity and those with type
2 DM, have significantly lower testosterone levels
than age-matched normal-weight and nondiabetic
controls. The mechanism underlying the low testos-
terone levels associated with insulin resistance in
men has not been clarified. Recently, Pitteloud et al
[37] reported a positive correlation between testoster-
one secretion and insulin sensitivity in men. They
found a clear association between increased insulin
resistance and decreased Leydig cell testosterone se-
cretion in men evaluated by the hyperinsulinemic-
euglycemic clamp test. Their findings suggest that
the decreased serum testosterone levels in adult survi-
vors of childhood cancer treated with SCT might be
explained not only by primary gonadal dysfunction
due to the effect of irradiation and/or alkylating agents
before SCT but also by the presence of fatty liver and
insulin resistance. In addition, several clinical studies
have shown significant associations between low
SHBG levels and insulin resistance [38] and metabolic
syndrome [39]. Shin et al [40] clarified the association
between serum SHBG levels and nonalcoholic fatty
liver disease in patients with type 2 DM. SHBG levels
were lower in patients with high-grade nonalcoholic
fatty liver disease than in those without it, and
SHBG level was negatively correlated with HOMA-
IR score. In the present study, although plasma
SHBG level was positively correlated with serum tes-
tosterone level, it was not negatively correlated with
HOMA-IR, because of an insufficient number of pa-
tients for statistical analysis.
A few limitations of the present study need to be
considered when interpreting our findings. This longi-
tudinal retrospective study included a small number of
patients who underwent SCT in a single institution. In
a future study, we plan to analyze the relationship be-
tween testosterone level and degree of fatty liver both
in patients who underwent SCT and in patients who
received chemotherapy only. Our data require confir-
mation in a large group of patients.
In conclusion, we found significantly higher prev-
alences of fatty liver and insulin resistance with
1126 Biol Blood Marrow Transplant 18:1119-1127, 2012H. Hyodo et al.decreased serum testosterone levels in our patients
who underwent SCT to treat childhood cancer than
in those who did not. Even those patients who were
not overweight or obese were likely to develop fatty
liver after SCT. Furthermore, the degree of fatty
liver was associated with the degree of reduced serum
testosterone level. The incidence of late effects after
SCT in our study population increased with follow-
up time and did not appear to plateau. We strongly
recommend close monitoring of metabolic and
endocrine function in adult survivors of childhood
SCT in an effort to improve their quality of life.ACKNOWLEDGMENTS
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